4 results
Primary objective:the primary objective of the study is to evaluate the safety and to define the maximal tolerated dose or the maximal administered dose of CC-486 as a single agent, in combination with CBDCA or ABI-007 in subjects with relapsed or…
All primary and secondary objectives will compare zanubrutinib (also known as BGB-3111) plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation only.Primary:• To compare efficacy, as measured by…
To evaluate the long-term safety of zanubrutinib in patients with B-cell cancers who participated in a BeiGene parent study for zanubrutinib
The primary objective is to develop and validate non-invasive portal pressure measurement by MRI in patients with end-stage liverdisease (ESLD).